As Of	Filer	Filing¹	For·On·As	Docs:Size	Issuer		Filing Agent

 5/15/24  Acura Pharmaceuticals, Inc.       NT 10-Q     3/31/24    1:21K                                    Toppan Merrill/FA        
 5/14/24  Acura Pharmaceuticals, Inc.       8-K:1,2,9   5/10/24   11:241K                                   Toppan Merrill/FA        
  4/1/24  Acura Pharmaceuticals, Inc.       NT 10-K    12/31/23    1:20K                                    Toppan Merrill/FA        
 3/26/24  Acura Pharmaceuticals, Inc.       8-K:1,2,9   3/25/24   12:237K                                   Toppan Merrill/FA        
 3/18/24  Acura Pharmaceuticals, Inc.       8-K:1,2,9   3/14/24   11:234K                                   Toppan Merrill/FA        
 2/14/24  Acura Pharmaceuticals, Inc.       8-K:1,2,9   2/14/24   11:229K                                   Toppan Merrill/FA        
  2/2/24  Acura Pharmaceuticals, Inc.       8-K:4,9     1/30/24   11:204K                                   Toppan Merrill/FA        
 1/10/24  Acura Pharmaceuticals, Inc.       8-K:1,2,9    1/8/24   11:228K                                   Toppan Merrill/FA        
  1/2/24  Ross George K                     4          Director²   1:8K   Acura Pharmaceuticals, Inc.       Toppan Merrill/FA        
  1/2/24  Skelly William G                  4          Director²   1:8K   Acura Pharmaceuticals, Inc.       Toppan Merrill/FA        
  1/2/24  Thangaraj Immanuel                4          Director²   1:9K   Acura Pharmaceuticals, Inc.       Toppan Merrill/FA        
  1/2/24  Wesson Bruce F                    4          Dir.,Other² 1:8K   Acura Pharmaceuticals, Inc.       Toppan Merrill/FA        
12/21/23  Acura Pharmaceuticals, Inc.       8-K:1,2,9   12/7/23   11:217K                                   Toppan Merrill/FA        
 12/6/23  Acura Pharmaceuticals, Inc.       8-K:1,2,9   12/4/23   12:247K                                   Toppan Merrill/FA        
11/20/23  Seiser Robert A                   4          Officer²    1:6K   Acura Pharmaceuticals, Inc.       Toppan Merrill/FA        
11/20/23  Jones Robert B                    4          Officer²    1:6K   Acura Pharmaceuticals, Inc.       Toppan Merrill/FA        
11/20/23  Clemens Peter A                   4          Officer²    1:6K   Acura Pharmaceuticals, Inc.       Toppan Merrill/FA        
11/20/23  Brzeczko Albert W                 4          Officer²    1:6K   Acura Pharmaceuticals, Inc.       Toppan Merrill/FA        
 11/3/23  Acura Pharmaceuticals, Inc.       NT 10-Q     9/30/23    1:21K                                    Toppan Merrill/FA        
10/12/23  Acura Pharmaceuticals, Inc.       8-K:1,2,9  10/10/23   11:222K                                   Toppan Merrill/FA        

____________
¹	Filing/Form Types:
	4	Statement of Changes in Beneficial Ownership of Securities by an Insider — Form 4 { The Filer is an Insider² of the Issuer }.
	8-K	Current Report — Form 8-K { Item 1: Business & Operations;  2: Financial Info;  3: Securities & Trading;  4: Accountants & Accounting;  5: Governance & Management;  6: Asset-Backed Securities;  7: Disclosures;  8: Events;  9: Financials }.
	NT 10-K	Notice of a Late Filing of a Form 10-K Annual Report — Form 12b-25.
	NT 10-Q	Notice of a Late Filing of a Form 10-Q Quarterly Report — Form 12b-25.
²	Insider:  The Filer is a Director, Officer, 10% Owner and/or Other “insider” of the Issuer.